Dhvanit Shah, Garuda Therapeutics CEO
February 7, 2023 09:00 AM ESTUpdated 09:31 AM
Financing
Startups
Cell/Gene Tx

Blood stem cell ther­a­py mak­er Garu­da nabs $62M

Kyle LaHucik

Senior Reporter

Garu­da Ther­a­peu­tics brought in $62 mil­lion via a Se­ries B to take its off-the-shelf cell ther­a­pies in­to the clin­ic next year.

The Boston-area biotech wants …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times